Praveen Tipirneni is a seasoned biopharmaceutical executive with deep experience in drug development and building biotechnology companies through to successful exits. He most recently served as President and CEO of Morphic Therapeutic, where he led the company from its founding through its $3.2 billion acquisition by Eli Lilly. Prior to founding Morphic, Praveen served as Senior Vice President of Corporate Development and Global Strategy at Cubist Pharmaceuticals from 2006 until the company’s acquisition by Merck in 2015 for approximately $9 billion. Earlier in his career, Praveen was a member of the clinical team supporting the NDA and sNDA submissions for Cubicin, contributing to its growth into $1.2 billion peak sales. Prior to joining Cubist, he worked at Sun Microsystems and Covad Communications in corporate strategy, and at Deltagen in business development. He also served as a First Lieutenant in the U.S. Army.

Praveen holds a BS in Mechanical Engineering from Massachusetts Institute of Technology (MIT), an MD from McGill University, and an MBA in Healthcare Finance from the University of Pennsylvania’s Wharton School of Business. He completed his post-graduate residency in Internal Medicine at the University of Illinois, Chicago.